Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | LPL | P06858 | 1/20 | 0.50 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.50 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | ABAT | P80404 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | PLK1 | P53350 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17260633 | 0.97 | CA2 (0.50) | HRH3CA2LOXL2TAAR1LPL | |
| SCHEMBL921748 | 0.87 | ST14 (0.63) | CA2TAAR1 | |
| SCHEMBL142480 | 0.85 | LPL (0.62) | CA2TAAR1LPLLIPGHTR2A | |
| SCHEMBL394855 | 0.84 | HTR2A (0.61) | HRH3CA2LPLLIPGHTR2A | |
| SCHEMBL3068192 | 0.83 | TAAR1 (0.71) | CA2LOXL2TAAR1LPLLIPG | |
| Hydroxyamine SCHEMBL17181093 | 0.82 | LPL (0.61) | CA2TAAR1LPLLIPGHTR2A | |
| SCHEMBL395434 | 0.82 | HTR2A (0.72) | CA2LPLLIPGHTR2AMGLL | |
| Hydrochloric Acid SCHEMBL920409 | 0.82 | HTR2A (0.59) | HRH3CA2HTR2A | |
| Water SCHEMBL28941509 | 0.82 | LPL (0.59) | CA2TAAR1LPLLIPGHTR2A | |
| SCHEMBL9839848 | 0.82 | LPL (0.59) | CA2TAAR1LPLLIPGMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023173618-A1 | CYCLIC GD (III) COMPLEX, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 国科温州研究院(温州生物材料与工程研究所) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023114200-A2 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF | ALEXION PHARMACEUTICALS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20230117680-A1 | CYCLOPHILIN D INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| WO-2022150167-A2 | NOVEL MACROCYCLIC OPIOID PEPTIDES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-07-14 | — | — | WO | disclosed |
| US-20220002251-A1 | HUMAN TLR8-SELECTIVE AGONISTS | UNIVERSITY OF KANSAS (US) | 2022-01-06 | — | — | US | disclosed |
| WO-2021123394-A1 | G PROTEIN-COUPLED RECEPTOR MODULATORS AND A PHARMACEUTICAL COMPOSITION | UNIVERSITY OF COPENHAGEN (DK) | 2021-06-24 | — | — | WO | disclosed |
| EP-3096751-B1 | 12-EPI-PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2021-01-06 | — | — | EP | disclosed |
| EP-3002310-B1 | COMPOSITION FOR PREPARING POLYIMIDE-INORGANIC PARTICLE COMPOSITE, POLYIMIDE-INORGANIC PARTICLE COMPOSITE, ARTICLE, AND OPTICAL DEVICE | SAMSUNG ELECTRONICS CO LTD (KR) | 2020-11-25 | — | — | EP | disclosed |
| US-10226452-B2 | Benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-03-12 | — | — | US | disclosed |
| WO-2019028362-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | DYAX CORP. (US) | 2019-02-07 | — | — | WO | disclosed |
| US-6586356-B2 | Coordination catalyst | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-07-01 | — | — | US | disclosed |
| EP-1300425-A2 | Catalyst component for addition polymerization, process for producing said catalyst and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-04-09 | — | — | EP | disclosed |
| US-20030060579-A1 | Catalyst component for addition polymerization, process for producing catalyst for addition polymerization and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-03-27 | — | — | US | disclosed |
| EP-1275662-A1 | MODIFIED PARTICLE, SUPPORT, CATALYST COMPONENT FOR ADDITION POLYMERIZATION, CATALYST FOR ADDITION POLYMERIZATION, AND PROCESS FOR PRODUCING ADDITION POLYMER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-01-15 | — | — | EP | disclosed |
| CN-1376049-A | Method of lightening keratinous tissue by topical application of oxime compound containing compositions | PROCTER & GAMBLE (US) | 2002-10-23 | — | — | CN | disclosed |
| US-20020143124-A1 | Homogeneous type solid catalyst component or homogeneous type solid catalyst, process for production thereof and process for producing addition polymer with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-10-03 | — | — | US | disclosed |
| US-20010020075-A1 | Catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-09-06 | — | — | US | disclosed |
| EP-1113026-A2 | Catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-07-04 | — | — | EP | disclosed |
| CN-1201061-A | Chemical-ray sensitive polymer composition | TORAY CO LTD (JP) | 1998-12-09 | — | — | CN | disclosed |
| US-4792628-A | ANTIOXIDANTS, ANTIINFLAMMATORY AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117680-A1 | CYCLOPHILIN D INHIBITORS AND USES THEREOF | PPID, PPIF, PPIL1 | HRH3 4318/4885CA2 4397/4885LOXL2 2566/4885 |
| US-10226452-B2 | Benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments | ASAH1, ASAH2, ACER2 | HRH3 1452/4885CA2 40/4885LOXL2 152/4885 |
| US-20220002251-A1 | HUMAN TLR8-SELECTIVE AGONISTS | TLR7, TLR8, TLR9 | HRH3 254/4885CA2 4731/4885LOXL2 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.